Cantor Fitzgerald analyst Charles Duncan lowered the firm’s price target on Neurocrine to $127 from $132 and keeps an Overweight rating on the shares. Neurocrine reported Q4 Ingrezza net sales of $399M, which slightly exceeded the firm’s expectations, driven by the persistent increase in TRx throughout 2022 with 29% growth y/y in 4Q22, the seventh quarter of positive sequential growth, the analyst tells investors in a research note. The firm is bullish on long-term Ingrezza net sales, and anticipates a potential approval in Huntington’s disease chorea in 2023.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Neurocrine price target lowered to $131 from $133 at Citi
- Neurocrine price target lowered to $131 from $136 at Barclays
- Neurocrine price target lowered to $95 from $103 at Piper Sandler
- Neurocrine sees FY23 INGREZZA net product sales $1.67B-$1.77B
- Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023